AO Ordine Mauriziano di Torino - Leucemia Acuta Linfoblastica

GIMEMA: ALL2418

A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell

GIMEMA ALL2620

Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients

GIMEMA ALL2820

Newly diagnosed adult philadelphia Chromosome-positive lymphoblastic leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib

GIMEMA ALL2922

Combinazione di ponatinib e chemioterapia come trattamento di prima linea per i pazienti con leucemia acuta linfoblastica BCR/ABL1-like (LAL BCR/ABL1-like) – BALLik

GIMEMA INO-FIRTS

Multicenter Retrospective observational study analyzing infective complications and the clinical outcome of patients with acute lymphoblastic leukemia treated with inotuzumab ozogamicin